aDepartment of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom;
bDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool, United Kingdom;
cWirral University Teaching Hospital, Birkenhead, United Kingdom;
dLiverpool University Hospital Foundation Trust, Liverpool, United Kingdom;
eDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom; and
fGartnavel General Hospital, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom.
Correspondence to: Saye Khoo, MD, Infection Pharmacology Group, 3nd Floor, William Henry Duncan Building, 6 West Derby Street, University of Liverpool, Liverpool, L7 8TX (e-mail: [email protected]).
The authors have no funding or conflicts of interest to disclose. No specific funding was received for this work. The Liverpool HIV Drug Interactions website is funded by grants from Gilead, MSD, Thera Technologies, and ViiV Healthcare. C.M. has received a research grant from Gilead and honoraria for lectures from ViiV and MSD. D.B. has received speaker's honoraria from ViiV, Gilead, and Theratechnologies, Europe. F.M. has received educational grants and/or consultation honoraria from Gilead, ViiV, and MSD. S.K. has received funding from Gilead, Janssen, GSK, ViiV, Vir, and Ridgeback Biotherapeutics for research projects unrelated to this work, and speaker's honoraria from ViiV and Merck.
Abstract presented at International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2021, Online.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).
